Precigen
Commercializes PAPZIMEOS while developing selected gene and cell therapies.
$6.97
After-hours close+0.04 (+0.50%)
At close$6.94(−3.55%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.09 | — | — |
| Aug 2026 | −$0.01 | $0.05 | +514.3% |
| May 2026 | −$0.03 | −$0.02 | +33.3% |
| Mar 2026 | −$0.10 | −$0.01 | +90.0% |
| Nov 2025 | −$0.08 | −$0.11 | −37.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | $0.09 | — | — | $69.2M | — | — |
| Aug 4, 2026 | −$0.01 | $0.05 | +514.3% | $28.0M | $55.0M | +96.5% |
| May 13, 2026 | −$0.03 | −$0.02 | +33.3% | $20.8M | $23.3M | +11.8% |
| Mar 25, 2026 | −$0.10 | −$0.01 | +90.0% | $8.4M | $4.6M | −45.6% |
| Nov 13, 2025 | −$0.08 | −$0.11 | −37.5% | $8.3M | $2.9M | −64.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 19, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 14, 2024 | ||||||
| Feb 13, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 9, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 6, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 8, 2022 | ||||||
| May 9, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Nov 8, 2021 | ||||||
| Aug 9, 2021 | ||||||
| May 10, 2021 | ||||||
| Mar 1, 2021 | ||||||
| Nov 9, 2020 | ||||||
| Aug 10, 2020 | ||||||
| May 6, 2020 | ||||||
| Mar 2, 2020 | ||||||
| Nov 12, 2019 | ||||||
| Aug 8, 2019 | ||||||
| May 9, 2019 | ||||||
| Feb 28, 2019 | ||||||
| Nov 8, 2018 | ||||||
| Aug 13, 2018 | ||||||
| May 10, 2018 | ||||||
| Mar 1, 2018 | ||||||
| Nov 9, 2017 | ||||||
| Aug 9, 2017 | ||||||
| May 10, 2017 | ||||||
| Mar 1, 2017 | ||||||
| Nov 9, 2016 | ||||||
| Aug 9, 2016 | ||||||
| May 10, 2016 | ||||||
| Feb 29, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 10, 2015 | ||||||